Biopharma firm Zetagen raises $9.79m in Series B financing round

14 Aug 2023
www.pharmaceutical-technology.com
Phase 2Breakthrough TherapyFast Track
Biopharma firm Zetagen raises $9.79m in Series B financing round
Preview
Source: Pharmaceutical Technology
In preclinical research, Zetagen’s ZetaMAST showed potential to stop lesion growth. Credit: Zetagen.
Clinical-stage biopharma firm Zetagen Therapeutics has raised $9.79m in a Series B financing round to develop its treatments for metastatic cancers to bone and soft tissue organs.
The funding round saw participation from private investors including New York Ventures and Consolidated Capital Investments.
Recommended Reports
Biopharma firm Zetagen raises $9.79m in Series B financing round
Preview
Source: Pharmaceutical Technology
ReportsPharmaceuticals Industry Deals and Trends in April 2021 - Partnerships, Licensing, Investments, M... GlobalData
Biopharma firm Zetagen raises $9.79m in Series B financing round
Preview
Source: Pharmaceutical Technology
ReportsPharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes in Q1 2022 - Thematic Research GlobalData
View allCompanies IntelligenceZetaGen Therapeutics IncBio Pharma LimitedConsolidated Capital Investments LimitedNewYork VenturesView all
Zetagen will use the funding proceeds to develop its treatments, ZetaMAST and ZetaMet, and for research and development efforts for other oncologic and osteologic assets in the pipeline.
A percutaneous, intra-tumoural injection, ZetaMAST will be developed to treat metastatic lesions to soft tissue organs.
In preclinical research, it showed the potential to hinder lesion growth.
It is designed to be injected intra-tumourally into soft tissue organs such as the liver, lung and brain.
ZetaMet is currently being evaluated in Phase IIa clinical trials to treat metastatic breast cancer bone lesions as part of advanced-stage cancer treatment.
The firm was issued two breakthrough device designations by the US Food and Drug Administration (FDA) for ZetaMet and ZetaFuse, along with a number of patents from the US Patent and Trademark Office (USPTO).
Zetagen Therapeutics CEO Joe Loy stated: “We are pleased to have reached this key milestone in the advancement of Zetagen as a biopharmaceutical company.
“We have a robust and diverse pipeline of oncologic treatments in various stages of development and this funding will accelerate each asset, as well as build out the necessary expertise required to bring these important therapies to fruition.”
Zetagen also plans to include fresh talent to develop these programmes.
Zetagen Therapeutics co-founder Nikhil Thakur stated: “We believe the development of ZetaMet and ZetaMAST – as well as the company’s other clinical programmes – have the potential to make a significant contribution to the treatment of late-stage cancers and more importantly, to the lives of those living with late-stage cancer.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.